Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
enGene Holdings Inc. Common Stock(ENGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ENGN
09/25/2026: ENGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
enGene Holdings is a clinical-stage biotechnology company developing non-viral gene therapies, primarily focused on its lead asset, EG-70, for treating non-muscle invasive bladder cancer. The company's main strength lies in its proprietary DDX delivery platform, which aims to provide localized, safer treatment options. The primary growth story involves the successful progression of EG-70 through clinical trials toward potential commercialization. However, the company faces significant risks, including the inherent uncertainty of clinical outcomes, heavy reliance on a single lead asset, and the need for ongoing capital to fund operations. It is best suited for growth-oriented investors who can tolerate high volatility and long-term development timelines.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | The company offers high-growth potential linked to the success of its gene therapy pipeline. |
| Momentum investor | Mixed fit | Momentum is highly conditional on clinical data readouts and biotech market sentiment. |
| Value investor | Weak fit | The lack of current revenue and earnings makes the company unsuitable for traditional value-based metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | The high volatility and binary risks associated with clinical trials make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience extreme price swings based on news and clinical trial results. |
| Valuation risk | Medium / high | Valuation is speculative and relies on long-term projections of success in clinical trials. |
| Competition risk (bladder cancer therapeutics) | High | The company faces competition from established players with significant resources and commercial infrastructure. |
| Business quality | Medium | The business is early-stage, with its quality entirely dependent on the future efficacy of the proprietary DDX platform. |
| Dividend income | Low / none | There is no current or projected dividend policy. |
| Execution risk | High | The company must navigate complex regulatory and clinical trial pathways to successfully commercialize its lead asset. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 22.48% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 131.35M USD | Price to earnings Ratio - | 1Y Target Price 3.29 |
Price to earnings Ratio - | 1Y Target Price 3.29 | ||
Volume (30-day avg) 739.3K shares | Beta -0.27 | 52 Weeks Range 1.40 - 12.25 | Updated Date 09/26/2026 |
52 Weeks Range 1.40 - 12.25 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing EG-70 and the DDX platform; current operations are focused on spending capital to create future value. | The company currently burns cash to develop drugs and does not yet generate sales revenue. |
Earnings Date
Report Date 2026-09-08 | When Before Market | Estimate -0.44 | Actual 0.47 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32% | Return on Equity (TTM) -60.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -98.35M | Price to Sales(TTM) - |
Enterprise Value -98.35M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.01 | Shares Outstanding 67.02M | Shares Floating 32.75M |
Shares Outstanding 67.02M | Shares Floating 32.75M | ||
Percent Insiders 0.11 | Percent Institutions 84.1 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About enGene Holdings Inc. Common Stock
Exchange NASDAQ | Headquarters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.engene.com |
Full time employees 81 | Website https://www.engene.com | ||
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.